News - TP53 mutation - LARVOL VERI

Gain of function p53 mutant R273H confers distinct methylation profiles and consequent YAP/TAZ signaling mediated activation of partial or full EMT states to colon tumours. (PubMed, Epigenetics Chromatin)

We identified a distinct epigenetic signature associated with the p53 R273H mutation, characterised by hypomethylation of YAP/TAZ signalling genes that drives partial EMT and aggressive tumour behaviour. These findings highlight the importance of mutation-specific epigenetic regulation in shaping colorectal cancer progression and the need for developing therapeutic strategies tailored to p53 mutation status.

1 day ago

Journal • P53mut

TP53 (Tumor protein P53)

TP53 mutation

Real-World Outcomes and Treatment Patterns in Patients With Acute Myeloid Leukemia and TP53 Gene Mutation or 17p Deletion. (PubMed, Am J Hematol)

Real-World Outcomes and Treatment Patterns in Patients With Acute Myeloid Leukemia and TP53 Gene Mutation or 17p Deletion.

1 day ago

Journal • Real-world evidence

TP53 (Tumor protein P53)

TP53 mutation

AND logic-gated CRISPR/Cas9 and hybridization chain reaction system for precise ctDNA detection. (PubMed, J Nanobiotechnology)

Furthermore, we validated the specificity of our approach by successfully detecting various mutations, including KRAS G12C, KRAS G12D, EGFR T790M and TP53 R273H, in simulated clinical samples. These findings highlight a reliable method for precise ctDNA detection, offering high specificity, selectivity, and accuracy, thus paving the way for potential cancer diagnostic application.

1 day ago

Journal • Circulating tumor DNA

EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53)

TP53 mutation • KRAS mutation • EGFR mutation • KRAS G12C • EGFR T790M • KRAS G12D • KRAS G12

Thyroid-originated pleomorphic rhabdomyosarcoma with novel TP 53 intron frameshift mutation: a case report and literature review. (PubMed, World J Surg Oncol)

Under specific circumstances, CNB can provide an effective diagnostic approach for thyroid tumors. Moreover, in this case, we identified a novel TP53 intronic mutation that may drive the development of thyroid PRMS.

2 days ago

Journal

BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • NKX2-1 (NK2 Homeobox 1) • MYOD1 (Myogenic Differentiation 1)

TP53 mutation • BRAF V600E • BRAF V600 • RET mutation • RET rearrangement

Stromal fibroblastic mutant Trp53 promotes mammary tumor development via enhanced secretion of paracrine factors. (PubMed, NPJ Breast Cancer)

Consistently, supplementing primary HER2-positive tumor cultures with recombinant SAA1, SAA2, or THBS4 peptides enhanced tumor cell proliferation and migration. Together, these findings uncover a mechanism by which fibroblastic mutant p53 promotes mammary tumorigenesis-through upregulating secretory proteins such as SAA1, SAA2, and THBS4 in the stroma, thereby enhancing PI3K/AKT signaling and tumor progression.

2 days ago

Journal

HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • SAA1 (Serum Amyloid A1) • SAA2 (Serum Amyloid A2)

HER-2 positive • TP53 mutation • TP53 wild-type

Identification of high-risk signatures and therapeutic targets through molecular characterization and immune profiling of TP53-mutant breast cancer. (PubMed, J Genet Eng Biotechnol)

Our findings underscore the prognostic value of the identified genes and the immunosuppressive TME in TP53-mutant breast cancer. The identification of drug candidates with strong binding affinities to key proteins provides promising avenues for targeted therapy in this high-risk patient population.

2 days ago

Journal

ER (Estrogen receptor) • TP53 (Tumor protein P53) • FGFR4 (Fibroblast growth factor receptor 4) • CA9 (Carbonic anhydrase 9) • AGR3 (Anterior Gradient 3, Protein Disulphide Isomerase Family Member) • TFF1 (Trefoil Factor 1) • S100P (S100 calcium binding protein P)

TP53 mutation

Mekinist (trametinib) • docetaxel • lapatinib

Identifying actionable genetic mutations and microsatellite instability in liquid biopsy of colorectal cancer. (PubMed, J Genet Eng Biotechnol)

CRC genetic mutational statuses as well as contributing environmental stress factors such as gut microbiota dysbiosis are prognostically crucial, associated with high risk potential of gene-environment interactions based on machine learning.

2 days ago

Journal • Liquid biopsy • Microsatellite instability

TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MSI (Microsatellite instability) • FGFR3 (Fibroblast growth factor receptor 3) • KDR (Kinase insert domain receptor)

TP53 mutation • PIK3CA mutation

5-fluorouracil • capecitabine • leucovorin calcium

Transcriptome profiling by RNA sequencing reveals novel targets of Gemini nano curcumin on p53-mutant HT-29 colorectal cancer cells. (PubMed, J Genet Eng Biotechnol)

Our data reveal that nanocurcumin might affects HT-29 colorectal cancer cells through modulating different pathways such as endoplasmic reticulum response, and transporter-related genes. More studies necessitate to unravel the molecular mechanisms and proteins involved in these pathways that could be considered as novel therapeutic targets in colorectal cancer.

2 days ago

Journal • P53mut

TP53 (Tumor protein P53)

TP53 mutation

Integration of genomic and clinical variables improves the prediction of myelodysplastic syndromes to acute myeloid leukaemia transformation and prognosis. (PubMed, Br J Haematol)

This work provides the first genomic characterisation of a diagnosed MDS cohort in China and establishes the first risk prediction model for MDS-to-AML transformation, alongside novel prognostic models for OS and PFS. These tools offer improved prognostic prediction and potential guidance for therapeutic strategies in Chinese patients with MDS.

2 days ago

Journal

KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • DNMT3A (DNA methyltransferase 1) • NF1 (Neurofibromin 1) • JAK2 (Janus kinase 2) • SF3B1 (Splicing Factor 3b Subunit 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • ETV6 (ETS Variant Transcription Factor 6) • SRSF2 (Serine and arginine rich splicing factor 2) • BCOR (BCL6 Corepressor) • CSF3R (Colony Stimulating Factor 3 Receptor) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • STAG2 (Stromal Antigen 2) • GATA2 (GATA Binding Protein 2) • CALR (Calreticulin)

TP53 mutation • SRSF2 mutation • STAT3 mutation

E7386 in patients with advanced solid tumors: results from the dose-escalation part and an expansion part of a phase I study. (PubMed, ESMO Open)

In heavily pretreated patients with advanced solid tumors, E7386 demonstrated a manageable safety profile and a dose-dependent PK profile. PRs were noted in patients with small bowel carcinoma or desmoid tumor.

2 days ago

P1 data • Journal

KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • APC (APC Regulator Of WNT Signaling Pathway)

TP53 mutation • KRAS mutation

E7386

Surgical stage in the era of molecular profiling of endometrial cancer. (PubMed, Eur J Cancer)

Surgical stage remains a strong prognostic factor across molecular subtypes and should be considered alongside molecular classification when tailoring adjuvant treatment in EC.

2 days ago

Journal

TP53 (Tumor protein P53) • POLE (DNA Polymerase Epsilon)

TP53 mutation • MSI-H/dMMR • POLE mutation

APOBEC3B-driven mutations negatively regulated by P53 promote tumor progression and immunosuppressive microenvironment in prostate cancer. (PubMed, Mol Cell Biochem)

This infiltration may be mediated by cytokines and chemokines. Collectively, these findings suggest that A3B holds potential as a novel prognostic biomarker and immunotherapeutic target for PCa.

2 days ago

Journal • PD(L)-1 Biomarker • IO biomarker

CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD163 (CD163 Molecule) • APOBEC3B (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3B)

TP53 mutation